Newsroom | 5263 results

DULUTH, Ga.--(BUSINESS WIRE)--National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced that the Company is scheduled to present at the Morgan Stanley Global Consumer & Retail Conference on Wednesday, December 3, 2025, at 11:45 a.m. Eastern Time. A live webcast of the presentation can be accessed in the “Investors” section of the Company’s website at www.ir.nationalvision.com. The webcast will be archived and available on the website shortly after the...

NEW YORK--(BUSINESS WIRE)--Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 2, 2025 at 3:00 p.m. Eastern Time. The presentation will be webcast live over the internet and can be accessed at https://investors.warbyparker.com. An online archive will be available for a period of 90 days following the pr...

NEW YORK--(BUSINESS WIRE)--BTIG announced today that its 5th Annual Ophthalmology Day will take place on Monday, December 1, 2025. The virtual, one-day event will include thematic panel discussions and one-on-one meetings. The event will be hosted by: Ryan Zimmerman, BTIG Medical Technology Analyst Julian Harrison, BTIG Biotechnology Analyst Thomas Shrader, PhD, CFA, BTIG Biotechnology Analyst Justin Zelin, BTIG Biotechnology Analyst Jeet Mukherjee, BTIG Biotechnology Analyst “We are proud to c...

ミラン--(BUSINESS WIRE)--（ビジネスワイヤ） -- AGCバイオロジクスは、AAVantgardeによるシリーズB資金調達ラウンドの完了直後も、同バイオテクノロジー企業との新たな製造契約を発表しました。これは、アデノ随伴ウイルス市場におけるAGCバイオロジクスの最新の進展となります。本契約の下、同社は、現在承認された治療法が存在せず、進行性かつ不可逆的な視力低下に対応するために設計されたAAVantgardeの2つの新規候補品について、Good Manufacturing Practice（GMP）に基づく製造を提供します。 スタルガルト病を対象とする AAVB-039 。本治療法は、最も一般的な遺伝性の黄斑変性症に対応し、子どもおよび若年成人における主要な視力低下の原因となっている疾患を対象としているもので、約6,500人に1人が影響を受けます。AAVB-039は、米国、英国および欧州で進行中のファースト・イン・ヒューマン第1/2相臨床試験にあります。 網膜色素変性症（ アッシャー症候群1B型 によるもの）を対象とするAAVB-081。アッシャー症候群による網膜色...

MAILAND--(BUSINESS WIRE)--Nach dem Abschluss einer Serie-B-Finanzierungsrunde durch AAVantgarde hat AGC Biologics eine neue Produktionsvereinbarung mit dem Biotechnologieunternehmen bekannt gegeben. Damit hat AGC Biologics einen weiteren Meilenstein auf dem Markt für Adeno-assoziierte Viren erreicht. Im Rahmen dieser Vereinbarung wird AGC Biologics die GMP-konforme Herstellung für die beiden neuartigen Kandidaten von AAVantgarde übernehmen, die einen fortschreitenden und irreversiblen Sehverlus...

MILANO--(BUSINESS WIRE)--Dopo la chiusura di un round di finanziamento di serie B da parte di AAVantgarde, AGC Biologics ha annunciato un nuovo accordo di produzione con l'azienda biotech, che rappresenta il progresso più recente di AGC Biologics nel mercato dei virus adeno-associati. L'accordo prevede, da parte di AGC Biologics, la produzione basata sulle buone pratiche di fabbricazione di due nuovi candidati di AAVantgarde, disegnati per affrontare patologie che comportano la perdita progress...

MILAN--(BUSINESS WIRE)--On the heels of AAVantgarde closing a Series B financing round, AGC Biologics announced a new manufacturing agreement with the biotechnology company, marking AGC Biologics’ latest advancement in the adeno-associated virus market. Under this agreement, AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s two novel candidates designed to address progressive and irreversible vision loss where there are currently no approved therapies: AAVB-...

WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous NSCLC...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Executive Vice President and Chief Financial Officer Sam Eldessouky will participate in a fireside chat at the 2025 Citi Global Healthcare Conference on Wednesday, Dec. 3, 2025, at 9:00 a.m. ET. A live webcast, as well as a post-event recording, will be available on the I...

ATHERTON, Calif.--(BUSINESS WIRE)--TearOptix Secures Strategic Funding to Transform Presbyopia Treatment and Announces Creation of Scientific Advisory Board...